Ocular Therapeutix OCUL Income Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| $52.04M-12.8% | $51.95M-18.5% | $55.78M-9.2% | $56.66M-7.3% | $59.65M-0.3% | ||
| $6.64M+19.4% | $6.57M+16.9% | $6.21M+7.4% | $6M+7.1% | $5.56M+3.1% | ||
| $45.4M-16.1% | $45.38M-21.9% | $49.57M-10.9% | $50.67M-8.7% | $54.08M-0.7% | ||
| 87.2%-3.4pp | 87.3%-3.8pp | 88.9%-1.7pp | 89.4%-1.4pp | 90.7%-0.3pp | ||
| $220.45M+47.2% | $197.1M+54.4% | $187.29M+82.1% | $171.98M+113% | $149.76M+123% | ||
| $56.35M+23.7% | $53.92M+29.7% | $51.81M+29.5% | $49.29M+27.2% | $45.56M+14.2% | ||
| $68.03M+8.2% | $64.38M+6.1% | $61.32M+13.4% | $57.53M+14.1% | $62.85M+61.3% | ||
| $351.48M+33.3% | $321.97M+36.7% | $306.62M+51.3% | $284.8M+62.2% | $263.73M+74.3% | ||
| -$299.44M-46.7% | -$270.02M-57.2% | -$250.83M-77.6% | -$228.13M-99.3% | -$204.08M-123% | ||
| -575.4%-233pp | -519.8%-250pp | -449.7%-220pp | -402.6%-215pp | -342.2%-189pp | ||
| $11.63M-7.1% | $11.83M-12.8% | $12.11M-17.2% | $12.33M-16.8% | $12.51M-8.1% | ||
| $20.58M+1.9% | $18.35M-9.5% | $15.68M-8.1% | $17.61M+39.4% | $20.19M+175% | ||
| $8.94M— | $4.08M— | —— | —— | —— | ||
| -$290.5M-50.7% | -$265.94M-37.4% | -$249.67M-43.2% | -$216.75M-56.7% | -$192.71M-67.2% | ||
| -558.2%-235pp | -511.9%-208pp | -447.6%-164pp | -382.5%-156pp | -323.1%-130pp | ||
| -$1.44-26.3% | -$1.42-13.6% | -$1.43-17.2% | -$1.27-1.6% | -$1.14+8.8% | ||
| -$1.44-26.3% | -$1.42-13.6% | -$1.43-8.3% | -$1.27-14.4% | -$1.14-2.7% | ||
| 767.9M+16.3% | 713.2M+14.5% | 684.2M+24.3% | 667.2M+42.4% | 660.5M+73.4% | ||
| 767.9M+16.3% | 713.2M+14.5% | 684.2M+25.6% | 667.2M+46.0% | 660.5M+78.9% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| $20.58M+1.9% | $18.35M-9.5% | $15.68M-8.1% | $17.61M+39.4% | $20.19M+175% | ||
| $52.04M-12.8% | $51.95M-18.5% | $55.78M-9.2% | $56.66M-7.3% | $59.65M-0.3% | ||
| -$299.44M-46.7% | -$270.02M-57.2% | -$250.83M-77.6% | -$228.13M-99.3% | -$204.08M-123% | ||
| -$294.81M-47.2% | -$265.69M-58.2% | -$246.81M-79.5% | -$224.22M-102% | -$200.23M-127% | ||
| -$294.81M-47.2% | -$265.69M-58.2% | -$246.81M-79.5% | -$224.22M-102% | -$200.23M-127% | ||
| -566.5%-231pp | -511.4%-248pp | -442.4%-219pp | -395.7%-214pp | -335.7%-189pp | ||
| -$299.44M-46.7% | -$270.02M-57.2% | -$250.83M-77.6% | -$228.13M-99.3% | -$204.08M-123% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What is Ocular Therapeutix's revenue?
- Ocular Therapeutix (OCUL) generated $52.0M in revenue over the trailing twelve months, down 12.8% year over year.
- Is Ocular Therapeutix profitable?
- Ocular Therapeutix is not currently profitable: it reported a net loss of $290.5M over the trailing twelve months, a -558.2% net margin.
- What are Ocular Therapeutix's profit margins?
- Gross margin is 87.2% and operating margin is -575.4%, with a -558.2% net margin.
- What is Ocular Therapeutix's earnings per share?
- Ocular Therapeutix's diluted EPS over the trailing twelve months is $-1.44.
- Where does Ocular Therapeutix's income statement data come from?
- Every line is extracted from Ocular Therapeutix's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
